KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Alnylam Pharmaceuticals (ALNY) Prepaid Assets: 2009-2025

Historic Prepaid Assets for Alnylam Pharmaceuticals (ALNY) over the last 17 years, with Sep 2025 value amounting to $188.0 million.

  • Alnylam Pharmaceuticals' Prepaid Assets rose 29.37% to $188.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $188.0 million, marking a year-over-year increase of 29.37%. This contributed to the annual value of $117.0 million for FY2024, which is 7.45% down from last year.
  • According to the latest figures from Q3 2025, Alnylam Pharmaceuticals' Prepaid Assets is $188.0 million, which was up 27.64% from $147.3 million recorded in Q2 2025.
  • Alnylam Pharmaceuticals' 5-year Prepaid Assets high stood at $202.0 million for Q1 2024, and its period low was $76.0 million during Q1 2021.
  • In the last 3 years, Alnylam Pharmaceuticals' Prepaid Assets had a median value of $147.3 million in 2025 and averaged $150.5 million.
  • As far as peak fluctuations go, Alnylam Pharmaceuticals' Prepaid Assets soared by 69.67% in 2024, and later decreased by 24.53% in 2025.
  • Over the past 5 years, Alnylam Pharmaceuticals' Prepaid Assets (Quarterly) stood at $88.1 million in 2021, then surged by 50.91% to $132.9 million in 2022, then dropped by 4.92% to $126.4 million in 2023, then declined by 7.45% to $117.0 million in 2024, then climbed by 29.37% to $188.0 million in 2025.
  • Its last three reported values are $188.0 million in Q3 2025, $147.3 million for Q2 2025, and $152.4 million during Q1 2025.